Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative durvalumab plus chemotherapy for resectable non-small cell lung cancer
NL-OMON58718Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab perioperative arm with Placebo perioperative control arm (2 arms). Primary endpoints: Event-free survival and Pathological complete response. Started Sep 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58718.